<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912535</url>
  </required_header>
  <id_info>
    <org_study_id>D1443C00026</org_study_id>
    <nct_id>NCT00912535</nct_id>
  </id_info>
  <brief_title>Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms</brief_title>
  <official_title>Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy and safety of quetiapine extended
      release tablet versus placebo as adjunct to selective serotonin reuptake
      inhibitors/serotonin/norepinephrine reuptake inhibitors (SSRI/SNRI) in the augmentation
      treatment of patient with primary anxiety disorders or mood disorders with co-morbid anxiety
      symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale(HAMA-A) total score</measure>
    <time_frame>2 months</time_frame>
    <description>From baseline to Week 1, Week 4 and Week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Item scores for Abnormal Involuntary Movement Scale(AIMS)</measure>
    <time_frame>2 months</time_frame>
    <description>From baseline to Week 1, Week 4 and Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Item scores of Barnes-Akathisia Rating Scale (BARS)</measure>
    <time_frame>2 months</time_frame>
    <description>From baseline to Week 1, Week 4 and Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Item scores of Simpson-Angus Scale(SAS)</measure>
    <time_frame>2 months</time_frame>
    <description>From baseline to Week 1, Week 4 and Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>2 months</time_frame>
    <description>From baseline to Week 1, Week 4 and Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2 months</time_frame>
    <description>From baseline to Week 1, Week 4 and Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event/Serious adverse event</measure>
    <time_frame>8-9 weeks</time_frame>
    <description>From the time Informed Consent has been obtained to Week 1, Week 4 and Week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Primary Anxiety Disorders</condition>
  <condition>Mood Disorders With Comorbid Anxiety Symptoms</condition>
  <arm_group>
    <arm_group_label>Quetiapine extended release tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally, as adjunct to the same antidepressant at the same dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine extended release tablet</intervention_name>
    <description>Quetiapine extended release tablet of 50-300mg/day</description>
    <arm_group_label>Quetiapine extended release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally, as adjunct to the same antidepressant at the same dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  A diagnosis of primary anxiety disorder or mood disorder with co-morbid anxiety
             symptoms by Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition
             (DSM-IV)

          -  A 14-item Hamilton Anxiety Scale (HAM-A)&gt;= 14

          -  Subject have received single antidepressant at a therapeutic dose for at least 6 weeks

          -  Male or female aged 18-65 years

          -  Female patients of childbearing potential must be using a reliable method of
             contraception and have a negative urine human chorionic gonadotropin (HCG) test at
             enrollment

          -  Able to understand and comply with the requirements of the study and sign informed
             consent

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Any DSM-IV Axis I disorder not defined in the inclusion criteria.

          -  Receiving any anti-psychotic 7 days prior to entering the study

          -  Patients who, in the opinion of the investigator, post an imminent risk of suicide or
             a danger to self or others

          -  Known intolerance or lack of response to quetiapine fumarate, as judged by the
             investigator

          -  Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding
             enrollment including but not limited to: ketoconazole, itraconazole, fluconazole,
             erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,
             fluvoxamine and saquinavir

          -  Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding
             enrollment including but not limited to: phenytoin, carbamazepine, barbiturates,
             rifampin, St.John's Wort, and glucocorticoids

          -  Administration of a depot antipsychotic injection within one dosing interval (for the
             depot) before randomization

          -  Substance or alcohol dependence at enrollment (except dependence in full remission,
             and except for caffeine or nicotine dependence), as defined by DSM-IV criteria

          -  Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV
             criteria within 4 weeks prior to enrollment

          -  Medical conditions that would affect absorption, distribution, metabolism, or
             excretion of study treatment

          -  Unstable or inadequately treated medical illness (e.g. congestive heart failures,
             angina pectoris, hypertension) as judged by the investigator

          -  Involvement in the planning and conduct of the study

          -  Previous enrollment or randomization of treatment in the present study

          -  Participation in another drug trial within 4 weeks prior enrollment into this study or
             longer in accordance with local requirements

          -  A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:

               -  Unstable DM defined as enrollment glycosylated hemoglobin(HbA1c)&gt; 8.5%

               -  Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.

               -  Not under physician care for DM

               -  Physician responsible for patient's DM care has not indicated that patient's DM
                  is controlled

               -  Physician responsible for patient's DM care has not approved patient's
                  participation in the study

               -  Has not been on the same dose of oral hypoglycaemic drug(S) and/or diet for the 4
                  weeks prior to randomization. For thiazolidinediones(glitazones) this period
                  should not be less than 8 weeks

               -  Taking insulin whose daily dose on one occasion in the past 4 weeks has been more
                  than 10% above or below their mean dose in the preceding 4 weeks

          -  An absolute neutrophil count (ANC) of &lt;= 1.5x10(9) per liter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Ken Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Keelung</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2009</study_first_submitted>
  <study_first_submitted_qc>May 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>January 3, 2012</last_update_submitted>
  <last_update_submitted_qc>January 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chih-Ken Chen</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Primary Anxiety Disorders</keyword>
  <keyword>Mood Disorders with Comorbid Anxiety Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

